{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:25:29Z","timestamp":1793906729129,"version":"4.8.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.virol.2026.110821","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:59:52Z","timestamp":1769702392000},"page":"110821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs)"],"prefix":"10.1016","volume":"617","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9955-2261","authenticated-orcid":false,"given":"Subashan","family":"Vadibeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansini","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Atiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2026.110821_bib1","series-title":"Prescribing Information Dengvaxia","year":"2023"},{"key":"10.1016\/j.virol.2026.110821_bib2","series-title":"Dengvaxia: EPAR - Medicine Overview","author":"Agency","year":"2018"},{"key":"10.1016\/j.virol.2026.110821_bib3","series-title":"Qdenga: EPAR - Medicine Overview","author":"Agency","year":"2022"},{"key":"10.1016\/j.virol.2026.110821_bib4","series-title":"QDenga: SUMMARY OF PRODUCT CHARACTERISTICS","author":"Agency","year":"2022"},{"issue":"11","key":"10.1016\/j.virol.2026.110821_bib5","doi-asserted-by":"crossref","first-page":"e1680","DOI":"10.1016\/S2214-109X(23)00362-5","article-title":"Treatments for dengue: a global dengue alliance to address unmet needs","volume":"11","author":"Anasir","year":"2023","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.virol.2026.110821_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2023.102598","article-title":"Qdenga\u00ae - a promising dengue fever vaccine; can it be recommended to non-immune travelers?","volume":"54","author":"Angelin","year":"2023","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.virol.2026.110821_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.vhri.2024.01.003","article-title":"Tiered pricing and alternative mechanisms for equitative access to vaccines in Latin America: a narrative review of the literature","volume":"42","author":"Arango-Luque","year":"2024","journal-title":"Value Health Region. Issues"},{"issue":"7","key":"10.1016\/j.virol.2026.110821_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garc\u00eda","year":"2018","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.virol.2026.110821_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2024.101553","article-title":"Dengue in France in 2024 - a year of record numbers of imported and autochthonous cases","volume":"62","author":"Arulmukavarathan","year":"2024","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.virol.2026.110821_bib10","series-title":"ASEAN COMMON TECHNICAL DOSSIER (ACTD)","year":"2016"},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40794-024-00231-2","article-title":"The role of antibody-dependent enhancement in dengue vaccination","volume":"10","author":"Aynekulu","year":"2024","journal-title":"Tropical Diseases, Travel Med. Vaccines"},{"key":"10.1016\/j.virol.2026.110821_bib13","series-title":"ASEAN Regional Vaccine Manufacturing and Development","author":"Bank","year":"2023"},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/20539517211013868","article-title":"Towards psychological herd immunity: cross-cultural evidence for two prebunking interventions against COVID-19 misinformation","volume":"8","author":"Basol","year":"2021","journal-title":"Big Data Soc."},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00284-020-02284-w","article-title":"Current understanding of the pathogenesis of dengue virus infection","volume":"78","author":"Bhatt","year":"2021","journal-title":"Curr. Microbiol."},{"issue":"21","key":"10.1016\/j.virol.2026.110821_bib16","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10234","key":"10.1016\/j.virol.2026.110821_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"issue":"9951","key":"10.1016\/j.virol.2026.110821_bib18","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.virol.2026.110821_bib19","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2018.03.049","article-title":"Challenges for the registration of vaccines in emerging countries: differences in dossier requirements, application and evaluation processes","volume":"36","author":"Dellepiane","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110821_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102943","article-title":"Global, regional, and national burden of dengue infection in children and adolescents: an analysis of the global burden of disease study 2021","volume":"78","author":"Deng","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"7","key":"10.1016\/j.virol.2026.110821_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12919-023-00259-w","article-title":"Leading from the frontlines: community-oriented approaches for strengthening vaccine delivery and acceptance","volume":"17","author":"Dhaliwal","year":"2023","journal-title":"BMC Proc."},{"key":"10.1016\/j.virol.2026.110821_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2024.100777","article-title":"Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia\u00ae) in the state of Paran\u00e1, Brazil: integrating case-cohort and case-control designs","volume":"35","author":"Diaz-Quijano","year":"2024","journal-title":"The Lancet Region. Health \u2013 Americas"},{"key":"10.1016\/j.virol.2026.110821_bib24","article-title":"Alternative policies for pricing novel vaccines and drug therapies for COVID-19","author":"Emond","year":"2020","journal-title":"Institute for Clinical and Economic Review (ICER)"},{"issue":"2","key":"10.1016\/j.virol.2026.110821_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/v14020233","article-title":"Uncovering the burden of dengue in Africa: considerations on magnitude, misdiagnosis, and ancestry","volume":"14","author":"Gainor","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2026.110821_bib26","series-title":"Single-Dose Dengue Vaccine \u2018Will Help Amazon Communities\u2019","author":"Gavi","year":"2025"},{"key":"10.1016\/j.virol.2026.110821_bib27","series-title":"Annual Evaluation Report 2024","year":"2025"},{"issue":"Suppl. 12","key":"10.1016\/j.virol.2026.110821_bib30","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"issue":"9","key":"10.1016\/j.virol.2026.110821_bib31","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1080\/21645515.2018.1445448","article-title":"Safety issues from a phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine","volume":"14","author":"Halstead","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.virol.2026.110821_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40259-021-00495-6","article-title":"Vaccine-associated enhanced viral disease: implications for viral vaccine development","volume":"35","author":"Halstead","year":"2021","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.virol.2026.110821_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1056\/NEJMe2314240","article-title":"Three dengue vaccines\u2013what now","volume":"390","author":"Halstead","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.virol.2026.110821_bib34","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1016\/S2214-109X(24)00226-2","article-title":"Delivering safe dengue vaccines","volume":"12","author":"Halstead","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.virol.2026.110821_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.actatropica.2016.11.035","article-title":"Willingness to pay for a dengue vaccine and its associated determinants in Indonesia: a community-based, cross-sectional survey in Aceh","volume":"166","author":"Harapan","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.virol.2026.110821_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.893200","article-title":"Direct medical costs of tetanus, dengue, and sepsis patients in an intensive care unit in Vietnam","volume":"10","author":"Hung","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.virol.2026.110821_bib38","series-title":"Department of Health Urges Precautions as Dengue Outbreak Hits St. Thomas-St. John District","year":"2024"},{"key":"10.1016\/j.virol.2026.110821_bib39","series-title":"AAP, CDC Working to Vaccinate Children in Puerto Rico Against Dengue While Vaccine Remains Available","author":"Jenco","year":"2024"},{"key":"10.1016\/j.virol.2026.110821_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100299","article-title":"Trust and vaccine hesitancy during the COVID-19 pandemic: a cross-national analysis","volume":"14","author":"Jennings","year":"2023","journal-title":"Vaccine X"},{"issue":"5","key":"10.1016\/j.virol.2026.110821_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan\u2013dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.virol.2026.110821_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/21645515.2018.1522468","article-title":"Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness","volume":"15","author":"Larson","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/xap0000315","article-title":"Long-term effectiveness of inoculation against misinformation: three longitudinal experiments","volume":"27","author":"Maertens","year":"2021","journal-title":"J. Exp. Psychol. Appl."},{"issue":"32","key":"10.1016\/j.virol.2026.110821_bib44","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2012.02.064","article-title":"Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil","volume":"30","author":"Mahoney","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110821_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2019.00056","article-title":"Vaccine production in Africa: a feasible business model for capacity building and sustainable new vaccine introduction","volume":"7","author":"Makenga","year":"2019","journal-title":"Front. Public Health"},{"issue":"8","key":"10.1016\/j.virol.2026.110821_bib46","article-title":"Vaccine cold chain management in public health facilities of Oromia special zone, Amhara Region, Ethiopia: mixed study","volume":"10","author":"Mohammed","year":"2021","journal-title":"J. Drug Alcohol Res."},{"key":"10.1016\/j.virol.2026.110821_bib47","series-title":"Takeda to Launch Dengue Vaccine in India next Year","author":"Mukherjee","year":"2025"},{"issue":"9","key":"10.1016\/j.virol.2026.110821_bib48","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.vaccine.2018.11.050","article-title":"A cost analysis of producing vaccines in developing countries","volume":"37","author":"Munira","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40545-020-00281-9","article-title":"Establishment of the African medicines agency: progress, challenges and regulatory readiness","volume":"14","author":"Ncube","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"issue":"11","key":"10.1016\/j.virol.2026.110821_bib50","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","article-title":"Efficacy and safety of Butantan-DV in participants aged 2\u201359 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil","volume":"24","author":"Nogueira","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib51","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1038\/s41467-024-51018-0","article-title":"Molecular epidemiology and evolutionary characteristics of dengue virus 2 in East Africa","volume":"15","author":"Nyathi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2026.110821_bib52","series-title":"Ending the Neglect to Attain the Sustainable Development Goals: a Road Map for Neglected Tropical Diseases 2021\u20132030","article-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","author":"Organization","year":"2020"},{"key":"10.1016\/j.virol.2026.110821_bib53","series-title":"Pathogens Prioritization: a Scientific Framework for Epidemic and Pandemic Research Preparedness","author":"Organization","year":"2024"},{"issue":"10427","key":"10.1016\/j.virol.2026.110821_bib54","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(23)02576-X","article-title":"Dengue","volume":"403","author":"Paz-Bailey","year":"2024","journal-title":"Lancet"},{"issue":"685","key":"10.1016\/j.virol.2026.110821_bib55","doi-asserted-by":"crossref","first-page":"eadf1093","DOI":"10.1126\/scitranslmed.adf1093","article-title":"Vaccines for a sustainable planet","volume":"15","author":"Pecetta","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.virol.2026.110821_bib56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14760584.2016.1189331","article-title":"The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection","volume":"15","author":"Pitisuttithum","year":"2016","journal-title":"Expet Rev. Vaccine"},{"issue":"33","key":"10.1016\/j.virol.2026.110821_bib57","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing - an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.virol.2026.110821_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00705-023-05835-1","article-title":"Renaming of the genus flavivirus to orthoflavivirus and extension of binomial species names within the family flaviviridae","volume":"168","author":"Postler","year":"2023","journal-title":"Arch. Virol."},{"issue":"3","key":"10.1016\/j.virol.2026.110821_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.virol.2026.110821_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007213","article-title":"Global expansion and redistribution of Aedes-borne virus transmission risk with climate change","volume":"13","author":"Ryan","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2026.110821_bib61","series-title":"Announcement Regarding the Definitive Discontinuation of the manufacture\/import of DENGVAXIA\u00ae (Dengue 1, 2, 3, and 4 Vaccine, Recombinant and Attenuated)","year":"2025"},{"issue":"3","key":"10.1016\/j.virol.2026.110821_bib62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/vaccines11030575","article-title":"Knowledge, attitudes and practices toward dengue fever, vector control, and vaccine acceptance among the general population in countries from Latin America and Asia Pacific: a cross-sectional study (GEMKAP)","volume":"11","author":"Shafie","year":"2023","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.virol.2026.110821_bib63","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.vaccine.2003.09.019","article-title":"Cost-effectiveness of a pediatric dengue vaccine","volume":"22","author":"Shepard","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.virol.2026.110821_bib64","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2026.110821_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19073786","article-title":"Delay in vaccine access in ASEAN countries","volume":"19","author":"Subsittipong","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"2","key":"10.1016\/j.virol.2026.110821_bib66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.37719\/jhcs.2020.v2i2.oa005","article-title":"Dengue vaccine controversy awareness, vaccine health literacy, and vaccine acceptability among mothers in select rural communities","volume":"2","author":"Sumile","year":"2020","journal-title":"J. Health Caring Sci."},{"key":"10.1016\/j.virol.2026.110821_bib67","series-title":"Annual Integrated Report","author":"Takeda","year":"2024"},{"key":"10.1016\/j.virol.2026.110821_bib68","series-title":"Transforming Dengue Prevention","year":"2023"},{"issue":"12","key":"10.1016\/j.virol.2026.110821_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010966","article-title":"Epidemiology and costs of dengue in Thailand: a systematic literature review","volume":"16","author":"Thisyakorn","year":"2022","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"2","key":"10.1016\/j.virol.2026.110821_bib70","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.virol.2026.110821_bib71","series-title":"Immunization in the Asia-Pacific Region","first-page":"1466","author":"Tsai","year":"2017"},{"key":"10.1016\/j.virol.2026.110821_bib72","series-title":"United Nations Climate Change","article-title":"Operationalization of the funding arrangements for responding to loss and damage referred to in paragraph 2, including the fund referred to in paragraph 3, of decisions 2\/CP.27 and 2\/CMA.4","author":"UNFCoC","year":"2023"},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61205-0","article-title":"Vaccine hesitancy and trust in Sub-Saharan Africa","volume":"14","author":"Unfried","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2026.110821_bib74","series-title":"Costs of Fully Vaccinating a Child","year":"2024"},{"issue":"2","key":"10.1016\/j.virol.2026.110821_bib75","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2026.110821_bib76","unstructured":"Viruses ICoTo: ICTV Report Genus: Orthoflavivirus. In."},{"issue":"3","key":"10.1016\/j.virol.2026.110821_bib77","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3345\/cep.2024.00962","article-title":"Knowledge, attitude, and practice regarding dengue vaccine: a baseline study of community members and health providers in Indonesia","volume":"68","author":"Wahab","year":"2025","journal-title":"Clin. Exp. Pediatr."},{"issue":"1","key":"10.1016\/j.virol.2026.110821_bib78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41182-023-00564-2","article-title":"Lang\u2019at GC: Vaccine inequity: a threat to Africa's recovery from COVID-19","volume":"51","author":"Wei","year":"2023","journal-title":"Trop. Med. Health"},{"issue":"2","key":"10.1016\/j.virol.2026.110821_bib79","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2214-109X(23)00590-9","article-title":"TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden","volume":"12","author":"Wilder-Smith","year":"2024","journal-title":"Lancet Global Health"},{"issue":"10215","key":"10.1016\/j.virol.2026.110821_bib80","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(19)32525-5","article-title":"Vaccine-attributable severe dengue in the Philippines","volume":"394","author":"Wilder-Smith","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.virol.2026.110821_bib81","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1473-3099(24)00434-1","article-title":"Edging towards a third dengue vaccine","volume":"24","author":"Wilder-Smith","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"35","key":"10.1016\/j.virol.2026.110821_bib83","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1016\/j.vaccine.2021.07.051","article-title":"Fear, mistrust, and vaccine hesitancy: narratives of the dengue vaccine controversy in the Philippines","volume":"39","author":"Yu","year":"2021","journal-title":"Vaccine"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268222600036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268222600036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T17:15:45Z","timestamp":1771694145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004268222600036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":77,"alternative-id":["S004268222600036X"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.110821","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs)","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.110821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110821"}}